palbociclib

all catalysts(0)

nothing on the calendar yet

News(10)

• AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market
  SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.
  biospace · 19d ago
• AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
  The approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significant…
  biospace · 25d ago
• FDA Grants Accelerated Approval to a New Breast Cancer Treatment
  The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting ne…
  fda_press · 29d ago
• Pfizer expands multibillion-dollar cost-cutting plan
  Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.
  biopharma_dive · 2mo ago
• Celcuity gains FDA approval for closely watched breast cancer drug
  Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.
  biopharma_dive · 2mo ago
• Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
  Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
  biopharma_dive · 4mo ago
• RallyBio tries again for reverse merger, this time with Avenzo
  It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.
  biopharma_dive · 4mo ago
• The OncFive: Top Oncology Articles for the Week of 5/3
  The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.
  onclive · 4mo ago
• Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
  Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.
  onclive · 4mo ago
• ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
  Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
  onclive · 5mo ago